A Novel Targeted Therapy System for Cervical Cancer:  Co-Delivery System  of  Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

• Published in: International journal of nanomedicine Vol. 16; pp. 1051 - 1066
• Main Authors: Ye, Hui, Chu, Xiaoying, Cao, Zhensheng, Hu, Xuanxuan, Wang, Zihan, Li, Meiqi, Wan, Leyu, Li, Yongping, Cao, Yongge, Diao, Zhanqiu, Peng, Fengting, Liu, Jinsong, Xu, Lihua
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Animals; antisense lncrna of mdc1; Apoptosis; Apoptosis - drug effects; Apoptosis - genetics; Bladder cancer; Cancer; Cancer therapies; Cations; Cell Cycle Proteins - genetics; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; Cell Proliferation - genetics; Cervical cancer; Chemotherapy; Cholesterol; Cloning; Cytotoxicity; Deoxyribonucleic acid; DNA; Drug Carriers - chemistry; Drug Delivery Systems; Drug Liberation; Drugs; Experiments; Female; Gene Expression Regulation, Neoplastic - drug effects; Gene therapy; Genetic engineering; Health aspects; Humans; Laboratory animals; Liposomes; Magnetic fields; Magnetic Phenomena; magnetic thermosensitive cationic liposome; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Original Research; Oxalic acid; oxaliplatin; Oxaliplatin - pharmacology; Oxaliplatin - therapeutic use; Particle Size; Phase transitions; Prevention; Reagents; RNA, Long Noncoding - administration & dosage; Static Electricity; targeted therapy; Temperature; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Vehicles; Womens health; China; United Kingdom > UK; United States > US; targeted therapy; oxaliplatin; cervical cancer; magnetic thermosensitive cationic liposome; antisense lncRNA of MDC1
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/ijn.s258316

This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer. Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined. The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery. The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer.